Clinical characteristics and outcomes of COVID-19 in patients with type 2 diabetes in Turkey: A nationwide study (TurCoviDia).


Journal

Journal of diabetes
ISSN: 1753-0407
Titre abrégé: J Diabetes
Pays: Australia
ID NLM: 101504326

Informations de publication

Date de publication:
Jul 2021
Historique:
revised: 22 02 2021
received: 19 12 2020
accepted: 26 02 2021
pubmed: 4 3 2021
medline: 16 6 2021
entrez: 3 3 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) has been reported to be associated with a more severe course in patients with type 2 diabetes mellitus (T2DM). However, severe adverse outcomes are not recorded in all patients. In this study, we assessed disease outcomes in patients with and without T2DM hospitalized for COVID-19. A nationwide retrospective cohort of patients with T2DM hospitalized with confirmed COVID-19 infection from 11 March to 30 May 2020 in the Turkish Ministry of Health database was investigated. Multivariate modeling was used to assess the independent predictors of demographic and clinical characteristics with mortality, length of hospital stay, and intensive care unit (ICU) admission and/or mechanical ventilation. A total of 18 426 inpatients (median age [interquartile range, IQR]: 61 [17] years; males: 43.3%) were investigated. Patients with T2DM (n = 9213) were compared with a group without diabetes (n = 9213) that were matched using the propensity scores for age and gender. Compared with the group without T2DM, 30-day mortality following hospitalization was higher in patients with T2DM (13.6% vs 8.7%; hazard ratio 1.75; 95% CI, 1.58-1.93; P < .001). The independent associates of mortality were older age, male gender, obesity, insulin treatment, low lymphocyte count, and pulmonary involvement on admission. Older age, low lymphocyte values, and pulmonary involvement at baseline were independently associated with longer hospital stay and/or ICU admission. The current study from the Turkish national health care database showed that patients with T2DM hospitalized for COVID-19 are at increased risk of mortality, longer hospital stay, and ICU admission. 背景: 新冠肺炎(COVID-19)与2型糖尿病(T2DM)患者的病程密切相关。然而,并不是所有的患者都有严重的不良后果。在这项研究中,我们评估了有和没有因COVID-19住院的T2DM患者的疾病结局。 方法: 对2020年3月11日至5月30日在土耳其卫生部数据库中确诊为COVID-19的T2 DM患者进行全国性回顾性队列调查。多变量模型用于评估人口学和临床特征与死亡率、住院时间、重症监护病房(ICU)入院和/或机械通气的独立预测因素。 结果: 共调查18426例住院患者(中位年龄[四分位数范围,IQR]:61[17]岁;男性:43.3%)。T2 DM患者(n=9213)与非糖尿病患者(n=9213)进行年龄和性别倾向评分相匹配的比较。与非T2 DM组相比,T2 DM患者住院30d死亡率较高(13.6%比8.7%;危险比1.75;95%CI,1.58~1.93;P<0.001)。影响死亡率的独立因素是高龄、男性、肥胖、胰岛素治疗、淋巴细胞计数低和入院时肺部受累。年龄大、淋巴细胞值低和基线时肺部受累与较长的住院和/或ICU入院时间独立相关。 结论: 来自土耳其国家卫生保健数据库的研究显示,因COVID-19而住院的T2DM患者的死亡率、住院时间和ICU入院的风险增加。.

Sections du résumé

BACKGROUND BACKGROUND
Coronavirus disease 2019 (COVID-19) has been reported to be associated with a more severe course in patients with type 2 diabetes mellitus (T2DM). However, severe adverse outcomes are not recorded in all patients. In this study, we assessed disease outcomes in patients with and without T2DM hospitalized for COVID-19.
METHODS METHODS
A nationwide retrospective cohort of patients with T2DM hospitalized with confirmed COVID-19 infection from 11 March to 30 May 2020 in the Turkish Ministry of Health database was investigated. Multivariate modeling was used to assess the independent predictors of demographic and clinical characteristics with mortality, length of hospital stay, and intensive care unit (ICU) admission and/or mechanical ventilation.
RESULTS RESULTS
A total of 18 426 inpatients (median age [interquartile range, IQR]: 61 [17] years; males: 43.3%) were investigated. Patients with T2DM (n = 9213) were compared with a group without diabetes (n = 9213) that were matched using the propensity scores for age and gender. Compared with the group without T2DM, 30-day mortality following hospitalization was higher in patients with T2DM (13.6% vs 8.7%; hazard ratio 1.75; 95% CI, 1.58-1.93; P < .001). The independent associates of mortality were older age, male gender, obesity, insulin treatment, low lymphocyte count, and pulmonary involvement on admission. Older age, low lymphocyte values, and pulmonary involvement at baseline were independently associated with longer hospital stay and/or ICU admission.
CONCLUSIONS CONCLUSIONS
The current study from the Turkish national health care database showed that patients with T2DM hospitalized for COVID-19 are at increased risk of mortality, longer hospital stay, and ICU admission.
背景: 新冠肺炎(COVID-19)与2型糖尿病(T2DM)患者的病程密切相关。然而,并不是所有的患者都有严重的不良后果。在这项研究中,我们评估了有和没有因COVID-19住院的T2DM患者的疾病结局。 方法: 对2020年3月11日至5月30日在土耳其卫生部数据库中确诊为COVID-19的T2 DM患者进行全国性回顾性队列调查。多变量模型用于评估人口学和临床特征与死亡率、住院时间、重症监护病房(ICU)入院和/或机械通气的独立预测因素。 结果: 共调查18426例住院患者(中位年龄[四分位数范围,IQR]:61[17]岁;男性:43.3%)。T2 DM患者(n=9213)与非糖尿病患者(n=9213)进行年龄和性别倾向评分相匹配的比较。与非T2 DM组相比,T2 DM患者住院30d死亡率较高(13.6%比8.7%;危险比1.75;95%CI,1.58~1.93;P<0.001)。影响死亡率的独立因素是高龄、男性、肥胖、胰岛素治疗、淋巴细胞计数低和入院时肺部受累。年龄大、淋巴细胞值低和基线时肺部受累与较长的住院和/或ICU入院时间独立相关。 结论: 来自土耳其国家卫生保健数据库的研究显示,因COVID-19而住院的T2DM患者的死亡率、住院时间和ICU入院的风险增加。.

Autres résumés

Type: Publisher (chi)
背景: 新冠肺炎(COVID-19)与2型糖尿病(T2DM)患者的病程密切相关。然而,并不是所有的患者都有严重的不良后果。在这项研究中,我们评估了有和没有因COVID-19住院的T2DM患者的疾病结局。 方法: 对2020年3月11日至5月30日在土耳其卫生部数据库中确诊为COVID-19的T2 DM患者进行全国性回顾性队列调查。多变量模型用于评估人口学和临床特征与死亡率、住院时间、重症监护病房(ICU)入院和/或机械通气的独立预测因素。 结果: 共调查18426例住院患者(中位年龄[四分位数范围,IQR]:61[17]岁;男性:43.3%)。T2 DM患者(n=9213)与非糖尿病患者(n=9213)进行年龄和性别倾向评分相匹配的比较。与非T2 DM组相比,T2 DM患者住院30d死亡率较高(13.6%比8.7%;危险比1.75;95%CI,1.58~1.93;P<0.001)。影响死亡率的独立因素是高龄、男性、肥胖、胰岛素治疗、淋巴细胞计数低和入院时肺部受累。年龄大、淋巴细胞值低和基线时肺部受累与较长的住院和/或ICU入院时间独立相关。 结论: 来自土耳其国家卫生保健数据库的研究显示,因COVID-19而住院的T2DM患者的死亡率、住院时间和ICU入院的风险增加。.

Identifiants

pubmed: 33655669
doi: 10.1111/1753-0407.13171
pmc: PMC8013711
doi:

Substances chimiques

Blood Glucose 0
Glycated Hemoglobin A 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

585-595

Informations de copyright

© 2021 Ruijin Hospital, Shanghai JiaoTong University School of Medicine and John Wiley & Sons Australia, Ltd.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Diabetes Res Clin Pract. 2018 Dec;146:138-147
pubmed: 30244051
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Diabetes Care. 2020 Jul;43(7):1399-1407
pubmed: 32409498
Eur J Epidemiol. 2013 Feb;28(2):169-80
pubmed: 23407904
Front Immunol. 2020 Oct 27;11:579220
pubmed: 33193377
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
JCI Insight. 2019 Oct 17;4(20):
pubmed: 31550243
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Hypertens Res. 2020 Aug;43(8):824-831
pubmed: 32483311
Diabet Med. 2020 Jul;37(7):1146-1154
pubmed: 32392380
Diabetologia. 2020 Aug;63(8):1500-1515
pubmed: 32472191
J Clin Virol. 2020 Jun;127:104354
pubmed: 32305882
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
Diabetol Int. 2020 Sep 30;12(2):241-245
pubmed: 33020726
J Diabetes. 2021 Jul;13(7):585-595
pubmed: 33655669
Br J Nutr. 2000 Mar;83 Suppl 1:S5-8
pubmed: 10889785
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Circulation. 2020 Jul 7;142(1):4-6
pubmed: 32320270
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Diabetes Care. 2020 Jul;43(7):1382-1391
pubmed: 32409504
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Eur J Contracept Reprod Health Care. 2020 Jun;25(3):233-234
pubmed: 32469251
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
J Sports Sci. 2021 Mar;39(6):699-704
pubmed: 33118469
Diabetes Care. 2020 Oct;43(10):2339-2344
pubmed: 32769128
J Diabetes. 2021 Jan 23;:
pubmed: 33486896
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):535-545
pubmed: 32408118
N Engl J Med. 2018 Aug 16;379(7):633-644
pubmed: 30110583
Hypertens Res. 2020 Nov;43(11):1267-1276
pubmed: 32855527

Auteurs

Alper Sonmez (A)

Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Gulhane Faculty of Medicine and Gulhane Training and Research Hospital, Ankara, Turkey.

Ibrahim Demirci (I)

Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Gulhane Training and Research Hospital, Ankara, Turkey.

Cem Haymana (C)

Department of Endocrinology and Metabolism, University of Health Sciences Turkey, Gulhane Training and Research Hospital, Ankara, Turkey.

Ilker Tasci (I)

Department of Internal Medicine, University of Health Sciences Turkey, Gulhane Faculty of Medicine and Gulhane Training and Research Hospital, Ankara, Turkey.

Selcuk Dagdelen (S)

Department of Endocrinology and Metabolism, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Serpil Salman (S)

Department of Endocrinology and Metabolism, Medica Clinic, Istanbul, Turkey.

Naim Ata (N)

Department of Strategy Development, Republic of Turkey, Ministry of Health, Ankara, Turkey.

Ibrahim Sahin (I)

Department of Endocrinology and Metabolism, Faculty of Medicine, Malatya İnönü University, Malatya, Turkey.

Rifat Emral (R)

Department of Endocrinology and Metabolism, Faculty of Medicine, Ankara University, Ankara, Turkey.

Erman Cakal (E)

Department of Endocrinology and Metabolism, Faculty of Medicine, University of Health Sciences Turkey, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

Aysegul Atmaca (A)

Department of Endocrinology and Metabolism, Faculty of Medicine, Samsun 19 Mayis University, Samsun, Turkey.

Mustafa Sahin (M)

Department of Endocrinology and Metabolism, Faculty of Medicine, Ankara University, Ankara, Turkey.

Osman Celik (O)

Public Hospitals General Directorate, Republic of Turkey, Ministry of Health, Ankara, Turkey.

Tevfik Demir (T)

Department of Endocrinology and Metabolism, Faculty of Medicine, Dokuz Eylul University, Ankara, Turkey.

Derun Ertugrul (D)

Department of Endocrinology and Metabolism, Faculty of Medicine, University of Health Sciences Turkey, Kecioren Training and Research Hospital, Ankara, Turkey.

Ugur Unluturk (U)

Department of Endocrinology and Metabolism, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Murat Caglayan (M)

Ankara Provincial Health Directorate, Ankara, Turkey.

Ilhan Satman (I)

Department of Endocrinology and Metabolism, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Turkish Institute of Public Health and Chronic Diseases, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH